14 closest matches · ranked by relevance
Breast Enhancement
Primary: Number of Breasts With Successful Placement of the Implant Posterior to the Mammary Gland at 6 Weeks After Treatment — 48 Breasts
Gynecomastia
Primary: Analysis of Bilateral Occurrence of Adverse Events — 42; 38; 6; 7 Number of Events
Puberty, Precocious
Primary: Change in Growth Rate (cm/Year) — -1.62 cm/year — p=0.278
Women Who Have Had Breast Enhancement With Macrolane VRF
Primary: Number of Adverse Events — 46 number of AE
Breast Cancer
Primary: Objective Response Rate (ORR) — 37.5 percentage of participants
Hypogonadism · Severe Obesity
Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength
Breast Cancer
Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…
Hypogonadism
Primary: Change in Lean Body Mass — -2000; -1500 grams
Benign Breast Disease · Fibrocystic Disease of Breast · Fibroadenoma
Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants
Aging · Insulin Resistance
Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023
Hypogonadism
Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05
Breast Cancer
Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
Adverse Effects
Primary: Pharmacokinetic Parameters Based on Plasma Concentration of Lidocaine and MEGX in Nanograms/Milliliter. — NA; NA nanograms/mililiter — p=<0.05
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g